Log In
BCIQ
Print this Print this
 

PR509 (formerly SN32807)

  Manage Alerts
Collapse Summary General Information
Company Proacta Inc.
DescriptionHypoxia-activated irreversible pan-EGFR tyrosine kinase inhibitor
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor kinase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat erlotinib resistant non-small cell lung cancer (NSCLC)
Regulatory Designation
PartnerYakult Honsha Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/22/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today